MDGs and New Public-Private Partnerships

1,895 views

Published on

This presentation was made to a delegation of Nigerian National Assembly House Committee on MDGs, led by Hon. Saudatu Sani, who visited Johns Hopkins Bloomberg School of Public Health on December 1, 2008. This was part of a study tour of 18 parliamentarians plus staff to examine strategies to improve MDG outcomes in health, and to explore the roles that legislators may play in this process. This is a presentation from the Future Health Systems Research Programme Consortium (www.futurehealthsystems.org).

Published in: Health & Medicine, Business
  • Be the first to comment

MDGs and New Public-Private Partnerships

  1. 1. MDGs and New Public-Private Partnerships Oladimeji Oladepo University of Ibadan David Peters Johns Hopkins University
  2. 2. Countries on Track to Reach MDGs Nigeria Nigeria Nigeria Nigeria Nigeria Nigeria Nigeria Nigeria
  3. 3. Under 5 Mortality Rates (2004)
  4. 4. Purpose of Future Health Systems Research Consortium <ul><li>To generate knowledge that shapes health systems to benefit the world's poor </li></ul><ul><li>To translate political and financial commitments to meet the health needs of the poor into sustainable improvements in health and reductions in poverty </li></ul>
  5. 5. JHSPH, USA IDS, UK University of Ibadan, Nigeria Oladimeji Oladepo IPH, Uganda IIHMR, Afghanistan IIHMR, India CHEI, China ICDDR, B, Bangladesh
  6. 6. Study Background: Importance of Malaria in Nigeria <ul><li>Malaria a major cause of mortality and morbidity (About 25-35% of child deaths) and poverty </li></ul><ul><li>Resistance to conventional drugs (CQ, SP); Many substandard drugs available </li></ul><ul><li>New policy to provide ACTs as 1 st and 2 nd line drugs </li></ul><ul><li>Little known about the main source of treatment: Patent Medical Vendors (PMVs) </li></ul>
  7. 7. 54 Different Types of Anti-malarial Drugs Found in Oyo, Enugu & Kaduna
  8. 8. Percent of Patent Medical Vendor Shops with Anti-Malarial Drugs
  9. 9. Mean Price of Malaria Brands
  10. 10. Study Findings <ul><li>Low quality drugs cited as major problem by households, PMVs and Associations, government officials </li></ul><ul><li>Low confidence in government to regulate, but wide regional variation </li></ul><ul><li>PMVs know little about malaria policy change </li></ul><ul><li>Gov’t officials know nothing about PMV Associations </li></ul>
  11. 11. What are the Options? <ul><li>Business as usual </li></ul><ul><li>Educate parents, PMVs </li></ul><ul><li>Subsidize all ACTs </li></ul><ul><li>Support low-cost diagnostics </li></ul><ul><li>Support local institutions that work: civil society, PMV associations, gov’t regulators, industry, to monitor treatment/quality of drugs </li></ul>
  12. 12. FHS Nigeria: Developing Interventions <ul><li>New co-regulation with PMV Associations, citizens groups, government </li></ul><ul><li>Mini-Lab testing of drugs </li></ul><ul><li>Cell phone information on drugs, referrals </li></ul>
  13. 13. Next Steps <ul><li>Abuja Meeting </li></ul><ul><li>Making Health Markets Work for the Poor </li></ul><ul><li>January 12-13, 2009 </li></ul><ul><li>Innovators, potential collaborators, researchers to learn, gather resources and plan for implementation </li></ul>
  14. 14. Website: www.futurehealthsystems.org Email: [email_address]

×